Summary:
Pluristem Therapeutics, Inc. (NASDAQ: PSTI; DAX: PJT) is a bio-therapeutics Company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for the treatment of several severe degenerative, malignant and autoimmune disorders. The Company’s first planned product, PLX-I, targets a $3 billion annual market and is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT). Pluristem also believes its PLacental eXpanded (PLX) cells will be helpful for a variety of other indication, including as a help to patients afflicted with Peripheral Artery Disease (PAD) with critical limb ischemia (CLI).
Visit Pluristem Therapeutics, Inc..

Description (Web site quote):
Pluristem’s products are derived from mesenchymal stromal cells (MSCs) obtained from the placenta, a non-controversial source, and not from embryonic stem cells. The MSCs are then expanded in the Company’s proprietary PluriX™ 3D bioreactor. Pluristem's products are stored "ready to use" and have the potential to participate in the approximate $30 billion therapeutic and regenerative cellular market. Pluristem has offices in the USA with research and manufacturing facilities in Israel.
Visit Pluristem Therapeutics, Inc..